Literature DB >> 18182033

Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia.

D J Freeman1, K Tham, E A Brown, A Rumley, G D Lowe, I A Greer.   

Abstract

BACKGROUND: Pre-eclampsia is associated with increased placental debris circulating in maternal plasma.
OBJECTIVES: This study related placental debris to maternal markers of coagulation and endothelial activation in pre-eclampsia. PATIENTS/
METHODS: Circulating fetal corticotrophin-releasing hormone (CRH) mRNA and phosphatidylserine (PS)-exposing microparticles were assayed in third trimester plasma from women with pre-eclampsia (n = 32) and controls (n = 32) matched for age, body mass index, parity, and gestational age at sampling. Markers of maternal hemostasis and endothelial function were assessed.
RESULTS: Fetal CRH mRNA levels were higher in pre-eclampsia [mean 0.75 (SD 2.77) CRH/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA ratio] than in control pregnancies [0.20 (0.74), P = 0.014]. PS-exposing microparticle levels were not different between the groups. Women with pre-eclampsia had higher levels of tissue factor pathway inhibitor (TFPI), prothrombin F(1+2) fragment (F(1+2)), factor XIIa, soluble vascular cell adhesion molecule 1, von Willebrand factor and plasminogen activator inhibitor 1 than controls. Fetal CRH mRNA correlated with TFPI in pre-eclampsia and control groups (r = 0.38, P = 0.031, and r = 0.37, P = 0.039, respectively). Fetal CRH mRNA correlated with FVII activity (r = 0.43, P = 0.017) and PS-exposing microparticles correlated inversely with F(1+2) (r = -0.64, P < 0.001) in pre-eclampsia.
CONCLUSIONS: Placental debris, assessed by fetal CRH mRNA levels in maternal blood, is related to coagulation potential, i.e. FVII activity, but not to markers of coagulation or endothelial activation in pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182033     DOI: 10.1111/j.1538-7836.2007.02882.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.

Authors:  Lara Carvalho Godoi; Karina Braga Gomes; Patrícia Nessralla Alpoim; Maria das Graças Carvalho; Bashir A Lwaleed; Luci Maria Sant'Ana Dusse
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

2.  Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity.

Authors:  Chris Gardiner; Dionne S Tannetta; Carol A Simms; Paul Harrison; Christopher W G Redman; Ian L Sargent
Journal:  PLoS One       Date:  2011-10-14       Impact factor: 3.240

3.  Clinical and subclinical endometritis induced alterations in bovine endometrial transcriptome and miRNome profile.

Authors:  Dessie Salilew-Wondim; Sally Ibrahim; Samuel Gebremedhn; Dawit Tesfaye; Maike Heppelmann; Heinrich Bollwein; Christiane Pfarrer; Ernst Tholen; Christiane Neuhoff; Karl Schellander; Michael Hoelker
Journal:  BMC Genomics       Date:  2016-03-10       Impact factor: 3.969

4.  Fibrinolytic Changes in Women with Preeclampsia.

Authors:  Anne Cathrine Godtfredsen; Johannes Jakobsen Sidelmann; Britta Blume Dolleris; Jan Stener Jørgensen; Emma Kathrine Jungjohan Johansen; Melissa Fernard Bøg Pedersen; Yaseelan Palarasah; Jørgen Brodersen Gram
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

5.  The Role of RNAs and microRNAs in Non-Invasive Prenatal Diagnosis.

Authors:  Antonio Farina
Journal:  J Clin Med       Date:  2014-05-06       Impact factor: 4.241

6.  Controlled ovarian hyperstimulation induced changes in the expression of circulatory miRNA in bovine follicular fluid and blood plasma.

Authors:  Sina Seifi Noferesti; Md Mahmodul Hasan Sohel; Michael Hoelker; Dessie Salilew-Wondim; Ernst Tholen; Christian Looft; Franca Rings; Christiane Neuhoff; Karl Schellander; Dawit Tesfaye
Journal:  J Ovarian Res       Date:  2015-12-09       Impact factor: 4.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.